低剂量放疗增强诱导化疗在头颈癌中的效果:一项前瞻性2期试验结果
该前瞻性2期试验评估低剂量分次放疗(LDFRT)增强卡铂和紫杉醇诱导化疗在局部晚期头颈部鳞状细胞癌(SCCHN)中的疗效。共24例可评估患者,原发部位完全缓解率为62.5%,总生存期、无进展生存期和疾病特异性生存期的9年率分别为49.4%、72.2%和65.4%。结论认为LDFRT联合化疗有效且毒性低于更强烈的三药诱导方案。
要点
- LDFRT联合卡铂和紫杉醇诱导化疗在局部晚期SCCHN中原发部位缓解率达95.8%。
- 中位随访7.75年,9年总生存率为49.4%,中位总生存期为107.2个月。
- 3/4级毒性主要包括中性粒细胞减少(20%)和白细胞减少(32%)。
核心结论
- LDFRT增强紫杉醇和卡铂化疗在SCCHN中有效,中位总生存期达107.2个月,中位PFS未达到。
- 该方案毒性低于更强烈的三药诱导方案,且疗效与既往研究相比具有优势。
研究设计与样本
- 前瞻性2期试验,共纳入24例可评估的局部晚期SCCHN患者。
- 诱导治疗每21天为一周期,共两周期:紫杉醇75 mg/m2(第1、8、15天),卡铂AUC 6(第1天),LDFRT 50 cGy分次(第1、2、8、15天各2次)。
主要发现
- 原发部位缓解率为23/24(95.8%),其中完全缓解15/24(62.5%),部分缓解8/24(33.3%),疾病稳定1/24(4.2%)。
- 中位随访7.75年,9年总生存率为49.4%(95%CI 30.5-79.9),无进展生存率为72.2%(95%CI 55.3-94.3),疾病特异性生存率为65.4%(95%CI 44.3-96.4)。
- 3/4级毒性包括中性粒细胞减少(20%)、白细胞减少(32%)、脱水/低血压(8%)、贫血(4%)、感染(4%)、肺部/过敏性鼻炎(4%)和腹泻(4%)。
关键数值与推荐
- 原发部位完全缓解率为62.5%(15/24)。
- 9年总生存率为49.4%(95%CI 30.5-79.9),无进展生存率为72.2%(95%CI 55.3-94.3),疾病特异性生存率为65.4%(95%CI 44.3-96.4)。
- 中位总生存期为107.2个月,中位无进展生存期未达到。
临床怎么用
- LDFRT可作为化疗增敏剂与紫杉醇和卡铂联合用于局部晚期SCCHN的诱导治疗。
- 该方案毒性较低,可能为不适合强烈三药诱导方案的患者提供替代选择。
局限性
- 样本量较小(24例可评估患者),为单臂2期试验,需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Low-dose fractionated radiation therapy (LDFRT) induces effective cell killing through hyperradiation sensitivity and potentiates effects of chemotherapy. We report our second investigation of LDFRT as a potentiator of the chemotherapeutic effect of induction carboplatin and paclitaxel in locally advanced squamous cell cancer of the head and neck (SCCHN). EXPERIMENTAL DESIGN: Two cycles of induction therapy were given every 21 days: paclitaxel (75 mg/m2) on days 1, 8, and 15; carboplatin (area under the curve 6) day 1; and LDFRT 50 cGy fractions (2 each on days 1, 2, 8, and 15). Objectives included primary site complete response rate; secondary included overall survival, progression-free survival (PFS), disease-specific survival, and toxicity. RESULTS: A total of 24 evaluable patients were enrolled. Primary sites included oropharynx (62.5%), larynx (20.8%), oral cavity (8.3%), and hypopharynx (8.3%). Grade 3/4 toxicities included neutropenia (20%), leukopenia (32%), dehydration/hypotension (8%), anemia (4%), infection (4%), pulmonary/allergic rhinitis (4%), and diarrhea (4%). Primary site response rate was 23/24 (95.8%): 15/24 (62.5%) complete response, 8/24 (33.3%) partial response, and 1/24 (4.2%) stable disease. With median follow-up of 7.75 years, 9-year rates for overall survival were 49.4% (95% confidence interval [CI], 30.5-79.9), PFS was 72.2% (CI, 55.3-94.3), and disease-specific survival was 65.4% (44.3-96.4). CONCLUSION: Chemopotentiating LDFRT combined with paclitaxel and carboplatin is effective in SCCHN and provided an excellent median overall survival of 107.2 months, with median PFS not yet reached in this locally advanced SCCHN cohort. This compares favorably to prior investigations and caused fewer grade 3 and 4 toxicities than more intensive, 3-drug induction regimens. This trial demonstrates the innovative use of LDFRT as a potentiator of chemotherapy.
引用
- Arnold SM, Kudrimoti M, Dressler EV, et al. Using low-dose radiation to potentiate the effect of induction chemotherapy in head and neck cancer: Results of a prospective phase 2 trial. Adv Radiat Oncol. 2016. PMID: 28740895. doi:10.1016/j.adro.2016.06.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。